Oluyemi Okupe Sells 9,217 Shares of Hims & Hers Health (NYSE:HIMS) Stock

Hims & Hers Health, Inc. (NYSE:HIMS - Get Free Report) CFO Oluyemi Okupe sold 9,217 shares of the firm's stock in a transaction dated Friday, March 20th. The stock was sold at an average price of $23.77, for a total transaction of $219,088.09. Following the sale, the chief financial officer owned 318,789 shares of the company's stock, valued at approximately $7,577,614.53. The trade was a 2.81% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink.

• MarketBeat Week in Review – 03/09 - 03/13

Oluyemi Okupe also recently made the following trade(s):

• On Tuesday, January 20th, Oluyemi Okupe sold 9,067 shares of Hims & Hers Health stock. The stock was sold at an average price of $30.34, for a total transaction of $275,092.78.
• On Monday, January 5th, Oluyemi Okupe sold 9,070 shares of Hims & Hers Health stock. The shares were sold at an average price of $33.79, for a total transaction of $306,475.30.

Hims & Hers Health Stock Performance

Hims & Hers Health stock opened at $20.89 on Thursday. The firm has a 50 day simple moving average of $22.18 and a 200-day simple moving average of $36.18. The stock has a market cap of $4.76 billion, a price-to-earnings ratio of 40.95, a price-to-earnings-growth ratio of 2.47 and a beta of 2.55. The company has a debt-to-equity ratio of 1.80, a current ratio of 1.90 and a quick ratio of 1.70. Hims & Hers Health, Inc. has a 1-year low of $13.74 and a 1-year high of $70.43.

---

---

• Patience Pays: Hims & Hers Surges on News of Novo Nordisk Deal

Hims & Hers Health (NYSE:HIMS - Get Free Report) last released its quarterly earnings results on Monday, February 23rd. The company reported $0.08 EPS for the quarter, beating the consensus estimate of $0.02 by $0.06. Hims & Hers Health had a net margin of 5.47% and a return on equity of 22.48%. The firm had revenue of $617.82 million for the quarter, compared to analyst estimates of $619.48 million. During the same quarter in the previous year, the company earned $0.11 EPS. The business's revenue for the quarter was up 28.4% compared to the same quarter last year. On average, analysts expect that Hims & Hers Health, Inc. will post 0.29 EPS for the current year.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on the company. Weiss Ratings reaffirmed a "hold (c)" rating on shares of Hims & Hers Health in a research note on Monday, December 29th. Morgan Stanley cut their price objective on Hims & Hers Health from $40.00 to $21.00 and set an "equal weight" rating for the company in a research report on Tuesday, February 24th. Deutsche Bank Aktiengesellschaft boosted their price objective on shares of Hims & Hers Health from $25.00 to $28.00 and gave the company a "hold" rating in a report on Tuesday, March 10th. Zacks Research raised shares of Hims & Hers Health from a "strong sell" rating to a "hold" rating in a research report on Wednesday, February 25th. Finally, Truist Financial reiterated a "hold" rating and set a $18.00 price target (down from $37.00) on shares of Hims & Hers Health in a research report on Tuesday, February 24th. Three analysts have rated the stock with a Buy rating, thirteen have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of "Hold" and a consensus target price of $31.29.

• MarketBeat Week in Review – 02/23 - 02/27

View Our Latest Analysis on Hims & Hers Health

Trending Headlines about Hims & Hers Health

Here are the key news stories impacting Hims & Hers Health this week:

• Positive Sentiment: Settlement with Novo Nordisk removes a major legal overhang and clears the way for Hims to offer branded drugs — a catalyst for revenue and margin expansion that the market may not have fully priced in. Hims & Hers: Distressed Valuations Will Not Last For Long
• Positive Sentiment: Post‑earnings momentum: analysts and articles note HIMS is up roughly 38% since the last report after an EPS beat (reported 2/23) and continued subscriber/revenue growth — this underpins the recent upward move. Why Is Hims & Hers Health (HIMS) Up 38% Since Last Earnings Report?
• Neutral Sentiment: Comparative coverage (HIMS vs. DOCS) is highlighting differing business models and valuation paths — useful framing for investors but not an immediate stock catalyst. HIMS vs. DOCS: Which Digital Health Stock Offers Better Upside Now?
• Neutral Sentiment: Other analyst comparisons (INSP, TIVC, value‑investor writeups) provide context on relative valuation and investor audience but don't change the company fundamentals. INSP vs. HIMS: Which Stock Should Value Investors Buy Now?
• Negative Sentiment: Shareholder litigation: the Schall Law Firm has opened a securities‑fraud investigation into HIMS, which introduces regulatory/legal risk and can pressure sentiment until resolved. HIMS Investors Have Opportunity to Join Hims & Hers Health, Inc. Fraud Investigation
• Negative Sentiment: Insider selling: CFO Oluyemi Okupe sold ~9.2k shares (~2.8% reduction in his holding), and analysts have flagged persistent insider sales and disclosure changes as dampening sentiment. That selling can weigh on the stock, particularly given prior valuation compression. SEC Form 4 — Insider Sale

Institutional Investors Weigh In On Hims & Hers Health

A number of hedge funds have recently added to or reduced their stakes in the business. Vanguard Group Inc. boosted its position in Hims & Hers Health by 7.2% in the 4th quarter. Vanguard Group Inc. now owns 20,925,666 shares of the company's stock valued at $679,456,000 after buying an additional 1,407,651 shares during the period. Capital World Investors grew its stake in shares of Hims & Hers Health by 1.2% in the third quarter. Capital World Investors now owns 18,783,194 shares of the company's stock worth $1,065,399,000 after acquiring an additional 223,892 shares in the last quarter. Farallon Capital Management LLC increased its position in shares of Hims & Hers Health by 30.8% during the third quarter. Farallon Capital Management LLC now owns 10,746,852 shares of the company's stock worth $609,561,000 after acquiring an additional 2,533,271 shares during the period. State Street Corp raised its stake in shares of Hims & Hers Health by 1.8% in the fourth quarter. State Street Corp now owns 7,305,525 shares of the company's stock valued at $237,210,000 after acquiring an additional 132,311 shares in the last quarter. Finally, Geode Capital Management LLC raised its stake in shares of Hims & Hers Health by 12.4% in the fourth quarter. Geode Capital Management LLC now owns 5,509,764 shares of the company's stock valued at $183,485,000 after acquiring an additional 608,950 shares in the last quarter. 63.52% of the stock is currently owned by institutional investors and hedge funds.

About Hims & Hers Health

(Get Free Report)

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients' doorsteps.

The company's product portfolio addresses key areas of men's and women's health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.

See Also

• Five stocks we like better than Hims & Hers Health

This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].